Protein Expression Market by Type (Escherichia Coli, Mammalian, Yeast, Cell Free, and Others), by Products (Reagents, Expression Vectors, Competent Cells, Instruments, and Services), by Application (Therapeutic, Industrial, and Research), by End User (Pharmaceuticals & Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others) - Global Outlook & Forecast 2022-2030
According to the deep-dive market assessment study conducted by Growth+ Reports, the protein expression market was pegged at ~US$ 2.88 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of ~11.4% from 2022 to 2030.
The rising prevalence of chronic diseases, particularly among the geriatric population, is creating a positive outlook for the market for therapeutic proteins such as vaccines, peptide hormones, therapeutic enzymes, cytokines, antibodies, and blood factors. However, the widespread use of biologics in the manufacturing process, as they play an important role in the treatment of various health issues, is favoring the market growth. Various advancements and innovations in mass spectrometry and molecular genetics that aid in accurate mass determination and protein characterization are driving the market growth.
Increasing demand for cell-free protein expression is positively impacting the market growth due to its ability to express toxic proteins, increase speed, and increase overall yields of functional, soluble, full-length proteins. Other factors, such as extensive R&D activities and rising product demand from pharmaceutical and biotechnology companies, are expected to propel the market forward.
Companies are investing in the research of protein expression systems such as baculovirus expression systems (insect cell expression systems), transient expression (mammalian cells), and stable expression. Because of the high effectiveness of protein therapies, there is a low risk of adverse effects, which pushing the market growth. Furthermore, with the advancement of genetic engineering, which has opened up a lot of new routes and opportunities for large-scale protein expression and isolation, the transient protein expression market is driving the global market.
Government regulations governing protein therapeutics and biologics production may hinder the growth of the protein expression market. Government regulations requiring biologics to undergo rigorous preclinical and clinical trials prior to regulatory approval, as well as the time-consuming process for biologic approval with regard to any individual's health and safety, are limiting the market growth.
Over the forecast period, North America offers significant opportunities to key players in the protein expression market. The United States, which has the most developed and lucrative protein expression market, now accounts for the majority of the global protein expression market. Some of the factors influencing the global protein expression market in the United States are research investments, an increase in the use of protein technology, and the region's rapidly developing pharmaceutical industry with technological advancement. Another factor driving the protein expression market in the United States is the presence of numerous companies conducting clinical trials. The North America market's potential for growth is being aided by the increased research focus of the US pharmaceutical industry. Proteomics-related opportunities have aided the sector's expansion in the United States.
However, the US FDA’s stringent regulatory requirements are impeding the growth of the protein expression market. Under FDA 101, the Center for Drug Evaluation and Research (CDER) regulates biological products such as gene therapy and vaccines. These regulations ensure the quality, safety, and efficacy of biological therapeutic products while also accelerating the development of innovations that make these products safer and more effective. The US FDA announced a fast-track initiative to review its drugs and biologics policy to accelerate the availability of therapies for patients with serious conditions, and orphan drugs for rare diseases while maintaining safety and efficacy standards.
The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period. Due to the rising penetration of contract research organizations and developing healthcare infrastructure in Asian countries such as India and China. The availability of a large genome pool, a large number of patients, the availability of skilled personnel, and less stringent regulation for biologics production in Asian countries have all contributed to the region's growth.
The global market for protein expression is fragmented. The companies represented have a diverse product portfolio with extensive features, as well as a strong geographical presence. Furthermore, these industry leaders meet the needs of major end users such as research laboratories, pharmaceutical, and biotechnology firms. Some prominent players in the global protein expression market are Bio Rad Laboratories Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., Merck KGaA, New England Biolabs Inc., Takara Bio Inc., Oxford Expression Technologies Ltd., Promega Corporation, Sigma-Aldrich Corporation, Qiagen NV.